Positive Allosteric Modulators Market

Positive Allosteric Modulators Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Positive allosteric modulators (PAM) increase agonist affinity and/or efficacy. Affinity is the ability of a substance to bind to a receptor and efficacy is the ability of a substance to activate a receptor. If efficacy is zero, the substance is considered an antagonist.
GABAA receptor positive allosteric modulators are positive allosteric modulator (PAM) molecules that raise the activity of the GABAA receptor protein in the vertebrate central nervous system. GABAA receptor PAMs used as drugs have primarily sedative and anxiolytic effects.
Allosteric modulators can also stabilize one of the normal configurations of a receptor. Examples of positive allosteric modulators are benzodiazepines and barbiturates. Benzodiazepines are used to treat anxiety, panic attacks, seizures, insomnia, etc.
Positive allosteric modulators are particularly advantageous for neurotransmitter receptors
A positive allosteric modulator only activates receptors when the endogenous agonist is present
Allosteric modulators are helpful to the understanding of the structural and physicochemical properties of substances, which could provide the principles and rationale for allosteric drug discovery
Allosteric modulators offer a number of theoretical advantages compared to their competitive counterparts

Globally, over 10 million people are living with Parkinson's disease (PD)
According to the World Health Organization (WHO), schizophrenia is a chronic and severe mental disorder affecting 20 million individuals across the world. This is projected to boost the growth of the global positive allosteric modulators market.
There are several diseases that lack drug therapy because of the difficulty in designing drugs to interact with the orthosteric sites. Therefore, use of allosteric modulators can provide better alternatives to the discovery of new drugs to treat these disorders. This factor is anticipated to fuel the growth of the global market.
However, side effects of medicines are expected to hamper the growth of the global positive allosteric modulators market during the forecast period. Severe side effects of barbiturate are lack of coordination, headache, vomiting, confusion, respiratory arrest, and death.

North America is projected to dominate the global positive allosteric modulators market during the forecast period due to increase in Parkinson's disease cases
According to the Parkinson's Foundation, in the U.S., around 930,000 people were suffering from Parkinson's disease in 2020, and the number is anticipated reach 1.2 million by end of 2030.
In the U.S., around 5.5 million people are affected with Alzheimer disease, and the global prevalence is estimated to be as high as 24 million
Rise in prevalence of Alzheimer disease is expected to drive the global positive allosteric modulators market during the forecast period
The prevalence of Parkinson’s disease in the U.K. is about one in 500 people, with around 127,000 people living with the disease presently. Rise in prevalence of Parkinson's disease is likely to augment the global market during the forecast period.

Global Positive Allosteric Modulators Market, by Disease Type

Global Positive Allosteric Modulators Market, by Drug Type

Global Positive Allosteric Modulators Market, by End-user

Global Positive Allosteric Modulators Market, by Region

North America
- U.S.
- Canada
Europe
- Germany
- U.K
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa